Return On Equity of Revance Therapeutics, Inc. from 30 Sep 2014 to 30 Sep 2024

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Revance Therapeutics, Inc. quarterly and annual Return On Equity in % history and change rate from 30 Sep 2014 to 30 Sep 2024.
  • Revance Therapeutics, Inc. Return On Equity for the quarter ending 30 Sep 2024 was 136%, a 92% decline year-over-year.
  • Revance Therapeutics, Inc. annual Return On Equity for 2023 was 503%.
  • Revance Therapeutics, Inc. annual Return On Equity for 2022 was -787%, a 333% decline from 2021.
  • Revance Therapeutics, Inc. annual Return On Equity for 2021 was -182%, a 111% decline from 2020.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Change (%)
Return On Equity, Annual (%)
Return On Equity, YoY Annual Change (%)

Revance Therapeutics, Inc. Quarterly Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
Q3 2024 136% -1637% -92% 01 Jul 2024 30 Sep 2024
Q2 2024 237% +1140% 01 Apr 2024 30 Jun 2024
Q1 2024 385% +1476% 01 Jan 2024 31 Mar 2024
Q4 2023 503% +1290% 01 Oct 2023 31 Dec 2023
Q3 2023 1772% +2234% 01 Jul 2023 30 Sep 2023
Q2 2023 -903% -406% -81% 01 Apr 2023 30 Jun 2023
Q1 2023 -1091% -817% -299% 01 Jan 2023 31 Mar 2023
Q4 2022 -787% -605% -333% 01 Oct 2022 31 Dec 2022
Q3 2022 -462% -333% -260% 01 Jul 2022 30 Sep 2022
Q2 2022 -498% -395% -383% 01 Apr 2022 30 Jun 2022
Q1 2022 -274% -180% -192% 01 Jan 2022 31 Mar 2022
Q4 2021 -182% -96% -111% 01 Oct 2021 31 Dec 2021
Q3 2021 -128% -43% -50% 01 Jul 2021 30 Sep 2021
Q2 2021 -103% -14% -16% 01 Apr 2021 30 Jun 2021
Q1 2021 -94% -8% -9.9% 01 Jan 2021 31 Mar 2021
Q4 2020 -86% -5% -6.1% 01 Oct 2020 31 Dec 2020
Q3 2020 -86% +2% +2.1% 01 Jul 2020 30 Sep 2020
Q2 2020 -89% -10% -12% 01 Apr 2020 30 Jun 2020
Q1 2020 -85% -10% -13% 01 Jan 2020 31 Mar 2020
Q4 2019 -81% -7% -10% 01 Oct 2019 31 Dec 2019
Q3 2019 -88% -24% -38% 01 Jul 2019 30 Sep 2019
Q2 2019 -79% -14% -21% 01 Apr 2019 30 Jun 2019
Q1 2019 -75% -9% -14% 01 Jan 2019 31 Mar 2019
Q4 2018 -74% -7% -10% 01 Oct 2018 31 Dec 2018
Q3 2018 -64% +4% +6.4% 01 Jul 2018 30 Sep 2018
Q2 2018 -65% -10% -19% 01 Apr 2018 30 Jun 2018
Q1 2018 -66% -16% -32% 01 Jan 2018 31 Mar 2018
Q4 2017 -67% -24% -56% 01 Oct 2017 31 Dec 2017
Q3 2017 -68% -31% -82% 01 Jul 2017 30 Sep 2017
Q2 2017 -55% -15% -37% 01 Apr 2017 30 Jun 2017
Q1 2017 -50% -10% -25% 01 Jan 2017 31 Mar 2017
Q4 2016 -43% -1% -3.6% 01 Oct 2016 31 Dec 2016
Q3 2016 -37% +4% +10% 01 Jul 2016 30 Sep 2016
Q2 2016 -40% -5% -13% 01 Apr 2016 30 Jun 2016
Q1 2016 -40% -9% -27% 01 Jan 2016 31 Mar 2016
Q4 2015 -42% -2% -5.8% 01 Oct 2015 31 Dec 2015
Q3 2015 -42% +35% +46% 01 Jul 2015 30 Sep 2015
Q2 2015 -36% 01 Apr 2015 30 Jun 2015
Q1 2015 -31% 01 Jan 2015 31 Mar 2015
Q4 2014 -39% 01 Oct 2014 31 Dec 2014
Q3 2014 -76% 01 Jul 2014 30 Sep 2014

Revance Therapeutics, Inc. Annual Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
2023 503% +1290% 01 Jan 2023 31 Dec 2023
2022 -787% -605% -333% 01 Jan 2022 31 Dec 2022
2021 -182% -96% -111% 01 Jan 2021 31 Dec 2021
2020 -86% -5% -6.1% 01 Jan 2020 31 Dec 2020
2019 -81% -7% -10% 01 Jan 2019 31 Dec 2019
2018 -74% -9% -14% 01 Jan 2018 31 Dec 2018
2017 -64% -21% -50% 01 Jan 2017 31 Dec 2017
2016 -43% -1% -3.6% 01 Jan 2016 31 Dec 2016
2015 -42% -2% -5.8% 01 Jan 2015 31 Dec 2015
2014 -39% 01 Jan 2014 31 Dec 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.